Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen registry

Matteo Filippini, Chiara Bazzani, Fabiola Atzeni, Piercarlo Sarzi Puttini, Antonio Marchesoni, Ennio Giulio Favalli, Roberto Caporali, Lorenzo Cavagna, Roberto Gorla

Research output: Contribution to journalArticle

Abstract

This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

Original languageEnglish
Article number416892
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen registry'. Together they form a unique fingerprint.

  • Cite this